BioSapien, a cutting-edge healthtech startup based in the UAE and US, has extended its pre-Series A funding round to over $8 million, welcoming Globivest as a strategic investor. This milestone brings fresh capital and leadership talent to power the next phase of BioSapien’s growth, innovation, and global expansion.
Founded in 2018 by Dr. Khatija Ali, BioSapien is best known for its flagship product, MediChip™, a revolutionary, 3D-printed, localized drug delivery platform. Designed to attach directly to tissue, MediChip™ offers slow-release cancer treatment with minimal systemic side effects, potentially transforming how targeted therapies are delivered.
New Capital, New Backers
The recent funding extension includes backing from:
- ✅ Globivest – the first women-led, gender lens VC fund in the MENA region
- ✅ Global Ventures – a leading MENA-based venture capital firm
- ✅ Golden Gate Ventures – Singapore-based investor focused on global tech innovation
- ✅ Dara Holdings – diversified investment group
Globivest’s investment aligns with its mission to fund startups that drive scalable health, social, and environmental impact. Their focus on WHO’s One Health model, which links human, animal, and environmental health, makes BioSapien a strong fit.
“BioSapien’s MediChip™ is a breakthrough in localized cancer treatment, scalable, precise, and aligned with our One Health mission,” said Dr. Laura-Joy Boulos, Partner at Globivest.
Scaling with Global Talent
Alongside the funding news, BioSapien announced the onboarding of 12 world-class executives across multiple functions. These strategic hires will boost the company’s capabilities in R&D, regulatory affairs, operations, and compliance.
- Joseph Borrello, PhD – Chief Technology Officer
- Sonia Ramamoorthy, MD MBA FACS – Head of Medical Affairs
- Agnes Westelinck, PharmD – Head of Regulatory (US)
- Dirk Richter, MD FACS – Head of Regulatory (UAE)
- David Briere, PhD – Director of Pharmacology
- Jerry Webb, BSc – Head of Quality
Additional key hires include experts in manufacturing, compliance, clinical development, and business operations, underscoring BioSapien’s commitment to building a globally competitive team.
“A business is only as good as its people,” said Dr. Khatija Ali, CEO of BioSapien. “It’s thrilling to be joined by such high-quality, diverse talent. Together, we’ll make precision medicine more accessible and impactful worldwide.”
Vision for the Future
This round of funding and new appointments position BioSapien for:
- Accelerated product development of MediChip™
- Global regulatory approvals and market access
- Long-term commercialization and scaling
BioSapien’s growth reflects a broader trend in personalized healthcare, where biotech and precision medicine intersect to deliver better outcomes with fewer side effects.
